At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 21 enrolled
Drug / intervention
pazopanib hydrochloride +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of GW786034 (Pazopanib) in Patients With Recurrent and/or Metastatic Invasive Breast Carcinoma
In Brief
A Phase 2 clinical trial evaluating pazopanib hydrochloride, pharmacological study, and 1 other intervention for Breast Cancer and 2 related conditions. Completed, enrolled 21 participants across 3 sites.
Detailed Summary
This phase II trial is studying how well giving pazopanib works in treating patients with recurrent or metastatic invasive breast cancer. Pazopanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesCanada
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2007
First PostedJul 2007
Primary CompletionJul 2009
Study CompletionAug 2013
TodayJul 2026
First PostedJul 31, 2007
Enrollment StartJun 1, 2007
Primary CompletionJul 1, 2009
Study CompletionAug 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 18.9 years ago
Interventions
pazopanib hydrochloridedrug
Given orally
pharmacological studyprocedure
Correlative studies
laboratory biomarker analysisprocedure
Correlative studies